Clinical outcomes associated with anti-Xa-monitored enoxaparin for venous thromboembolism prophylaxis.

John A SaundersSara R VazquezJoseph A HillDaniel M Witt
Published in: Pharmacotherapy (2023)
Thirty-day clinical outcomes in patients receiving enoxaparin for venous thromboembolism prophylaxis were not improved by anti-Xa monitoring. Our results support current evidence-based guideline recommendations against anti-Xa monitoring for patients receiving enoxaparin for venous thromboembolism prophylaxis.